Johnson & Johnson vs Arcus Biosciences, Inc. — Stock Comparison
Q·Score Breakdown
7.1
Bullish
Overall
5.7
Neutral
Quality
Health
Growth
Valuation
Sentiment
JNJ
High-quality business with 26% return on equity and 22% profit margins.
⚠ earnings contracting 53% year-over-year.
RCUS
Clean balance sheet with low leverage (0.3× debt-to-equity).
⚠ currently unprofitable (-143% margin).
Analyst Consensus
BUY
Target $252.42 (+11.1%)
24 analysts
BUY
Target $34.00 (+32.4%)
10 analysts
Fundamentals
JNJ
RCUS
26.3×
Trailing P/E
—
17.9×
Forward P/E
-7.3×
21.8%
Profit Margin
-142.9%
68.0%
Gross Margin
-111.7%
26.4%
ROE
-63.3%
9.9%
Revenue Growth
26.9%
-52.9%
Earnings Growth
—
0.33
Beta
0.86
—
Price / Book
—
$546.9B
Market Cap
$3.2B
$146 – $252
52-Week Range
$7 – $29
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →